Ready-to-use Dynabeads™ allows for simultaneous signalling to TCR/CD3 and CD28 for physiological activation and expansion of mouse T cells. This technology out-performs traditional home-brew activation methods (mitogens, ConA, soluble antibodies etc.), and is well documented in the published literature.

Dynabeads allow you to move from mouse studies to clinical research using the same technology platform for activation/expansion.

Here's a short overview of the available mouse products. For a more complete overview, check out this Product Selection Guide (pdf)

Product Starting sample Main benefits
Dynabeads Mouse T-Activator CD3/CD28 (0.4 ml)

Dynabeads Mouse T-Activator CD3/CD28 (2 ml)

Dynabeads Mouse T-Activator CD3/CD28 (10 ml)
Mouse spleen or lymph node cells, mouse T cell clones, mouse CD4+ and CD8+ T cell subsets. Artificial antigen-presenting cells, optimised for mouse T cell activation and expansion.

Also includes a new protocol for mouse Treg expansion.

References

The references listed below are among the many published papers documenting the performance of the Dynabeads technology for T cell activation and expansion:

  1. Berger, C. et al. (2003) CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy.Blood 101:476–484.
  2. Bonyhadi, M. et al. (2005) In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol 174:2366–2375.
  3. Hami, L. et al. (2003) Comparison of a static process and a bioreactor-based process for the GMP manufacture of autologous Xcellerated T cells for clinical trials. BioProcessing Journal Vol. 2 No. 6, November/December 2003.
  4. Levine, B.L. et al. (2002) Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreases CCR5 expression in HIV infection. Nat Med 8:47–53.
  5. Godfrey, W.R. et al. (2004) In vitro expanded human CD4+CD25+ T regulatory cells can markedly inhibit allogeneic dendritic cell stimulated MLR cultures. Blood 104:453–461.
  6. Coito, S. et al. (2004) Retrovirus-mediated gene transfer in human primary T lymphocytes induces an activation-and transduction/selection-dependent TCRBV repertoire skewing of gene-modified cells. Stem Cells Dev 13:71–81.
  7. Rapoport, A.P. et al. (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 11:1162–1163.